Journal Home
Search for

Volume 78, Issue 12, Pages e97-e103 (December 2009)


View previous. 21 of 22 View next.

Influence of the MedDRA® hierarchy on pharmacovigilance data mining results

Ronald K. Pearsona, Manfred Haubenbcd, David I. Goldsmithe, A. Lawrence Gouldf, David Madigang, Donald J. O’Haraa, Stephanie J. Reisingera, Alan M. HochbergaCorresponding Author Informationemail address

Received 17 November 2008; accepted 13 January 2009. published online 19 February 2009.

Abstract 

Purpose

To compare the results of drug safety data mining with three different algorithms, when adverse events are identified using MedDRA1 Preferred Terms (PT) vs. High Level Terms (HLT) vs. Standardised MedDRA Queries (SMQ).

Methods

For a representative set of 26 drugs, data from the FDA Adverse Event Reporting System (AERS) database from 2001 through 2005 was mined for signals of disproportionate reporting (SDRs) using three different data mining algorithms (DMAs): the Gamma Poisson Shrinker (GPS), the urn-model algorithm (URN), and the proportional reporting rate (PRR) algorithm. Results were evaluated using a previously described Reference Event Database (RED) which contains documented drug–event associations for the 26 drugs. Analysis emphasized the percentage of SDRs in the “unlabeled supported” category, corresponding to those adverse events that were not described in the U.S. prescribing information for the drug at the time of its approval, but which were supported by some published evidence for an association with the drug.

Results

Based on a logistic regression analysis, the percentage of unlabeled supported SDRs was smallest at the PT level, intermediate at the HLT level, and largest at the SMQ level, for all three algorithms. The GPS and URN methods detected comparable percentages of unlabeled supported SDRs while the PRR method detected a smaller percentage, at all three MedDRA levels. No evidence of a method/level interaction was seen.

Conclusions

Use of HLT and SMQ groupings can improve the percentage of unlabeled supported SDRs in data mining results. The trade-off for this gain is the medically less-specific language of HLTs and SMQs compared to PTs, and the need for the added step in data mining of examining the component PTs of each HLT or SMQ that results in a signal of disproportionate reporting.

a ProSanos Corporation, 225 Market St, Suite 502, Harrisburg, PA 17102, USA

b Pfizer Corporation, New York University School of Medicine, New York, NY, USA

c New York Medical College, Valhalla, NY, USA

d Brunel University, West London, UK

e Goldsmith Pharmacovigilance and Systems, New York, NY, USA

f Merck Research Laboratories, West Point, PA, USA

g Columbia University, New York, NY, USA

Corresponding Author InformationCorresponding author at: ProSanos Corporation, 225 Market St, Suite 502, Harrisburg, PA 17102, USA. Tel.: +1 717 635 2124.

1 MedDRA® is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

PII: S1386-5056(09)00003-3

doi:10.1016/j.ijmedinf.2009.01.001


View previous. 21 of 22 View next.